Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$73.15
1.011.40%
À la fermeture: -
$72.58
-0.57-0.78%
Après les heures de négociation: 7:38 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
CVS Health Corp a un objectif de cours consensus de $79.96, basé sur les évaluations des 25 analystes. Le plus élevé est de $96 attribué par Credit Suisse le mai 8, 2023, et le plus bas est de $65 attribué par Evercore ISI Group le janvier 27, 2025. Les 3 dernières évaluations d'analystes ont été publiées par Cantor Fitzgerald, UBS et Baird le août 26, 2025, août 18, 2025 et août 14, 2025. Avec un objectif de cours moyen de $79.67 entre Cantor Fitzgerald, UBS et Baird, il y a une variation implicite de 9.76% upside pour CVS Health Corp à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Cantor Fitzgerald
UBS
Baird
Morgan Stanley
Barclays
1calculé à partir des notes des analystes
Notes d'analystes pour CVS Health
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/26/2025 | 7.47% | Cantor Fitzgerald | $78 → $78 | Reiterates | Overweight → Overweight | |||
08/18/2025 | 8.85% | UBS | $67 → $79 | Upgrade | Neutral → Buy | |||
08/14/2025 | 12.98% | Baird | $71 → $82 | Upgrade | Neutral → Outperform | |||
08/01/2025 | 12.98% | Morgan Stanley | $80 → $82 | Maintains | Overweight | |||
08/01/2025 | 10.22% | Barclays | $79 → $80 | Maintains | Overweight | |||
07/22/2025 | -7.69% | UBS | $71 → $67 | Maintains | Neutral | |||
06/30/2025 | 10.22% | Jefferies | $74 → $80 | Maintains | Buy | |||
06/02/2025 | 8.85% | Barclays | $82 → $79 | Maintains | Overweight | |||
05/12/2025 | 15.73% | Truist Securities | $82 → $84 | Maintains | Buy | |||
05/06/2025 | 15.73% | Wells Fargo | $76 → $84 | Maintains | Overweight | |||
05/05/2025 | 11.6% | RBC Capital | $74 → $81 | Maintains | Outperform | |||
05/02/2025 | -2.18% | UBS | $67 → $71 | Maintains | Neutral | |||
05/02/2025 | 12.98% | Barclays | $73 → $82 | Maintains | Overweight | |||
04/15/2025 | -2.18% | Baird | $51 → $71 | Maintains | Neutral | |||
04/11/2025 | 12.98% | Truist Securities | $76 → $82 | Maintains | Buy | |||
04/09/2025 | 4.71% | Mizuho | $70 → $76 | Maintains | Outperform | |||
03/21/2025 | 1.96% | Piper Sandler | $72 → $74 | Maintains | Overweight | |||
02/18/2025 | 11.6% | JP Morgan | $80 → $81 | Maintains | Overweight | |||
02/13/2025 | 0.58% | Wells Fargo | $68 → $73 | Maintains | Overweight | |||
02/13/2025 | 4.71% | Truist Securities | $60 → $76 | Maintains | Buy | |||
02/13/2025 | 0.58% | Barclays | $71 → $73 | Maintains | Overweight | |||
02/13/2025 | 3.33% | Leerink Partners | $55 → $75 | Upgrade | Market Perform → Outperform | |||
01/27/2025 | -10.44% | Evercore ISI Group | $60 → $65 | Maintains | Outperform | |||
01/06/2025 | -17.33% | Truist Securities | $67 → $60 | Maintains | Buy | |||
12/03/2024 | -9.07% | Deutsche Bank | $66 → $66 | Upgrade | Hold → Buy | |||
11/25/2024 | 10.22% | TD Cowen | $73 → $80 | Maintains | Buy | |||
11/25/2024 | -11.82% | Piper Sandler | $72 → $64 | Maintains | Overweight | |||
11/20/2024 | -7.69% | Truist Securities | $76 → $67 | Reiterates | Buy → Buy | |||
11/18/2024 | -9.07% | Wells Fargo | $60 → $66 | Upgrade | Equal-Weight → Overweight | |||
11/15/2024 | -20.09% | RBC Capital | $68 → $58 | Maintains | Outperform | |||
11/07/2024 | -14.58% | UBS | $60 → $62 | Maintains | Neutral | |||
11/07/2024 | -2.18% | Barclays | $75 → $71 | Maintains | Overweight | |||
11/04/2024 | -17.33% | Wells Fargo | $61 → $60 | Maintains | Equal-Weight | |||
10/24/2024 | -9.07% | Mizuho | $73 → $66 | Maintains | Outperform | |||
10/23/2024 | 3.33% | Barclays | $82 → $75 | Maintains | Overweight | |||
10/11/2024 | 4.71% | Truist Securities | $66 → $76 | Maintains | Buy | |||
10/10/2024 | 12.98% | Barclays | $63 → $82 | Upgrade | Equal-Weight → Overweight | |||
10/08/2024 | 3.33% | Evercore ISI Group | $62 → $75 | Maintains | Outperform | |||
10/04/2024 | 17.11% | TD Cowen | $59 → $85 | Upgrade | Hold → Buy | |||
10/01/2024 | -14.58% | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
09/16/2024 | -14.58% | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
09/10/2024 | -14.58% | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
09/04/2024 | -6.31% | RBC Capital | $68 → $68 | Reiterates | Outperform → Outperform | |||
08/19/2024 | -14.58% | Cantor Fitzgerald | $62 → $62 | Reiterates | Neutral → Neutral | |||
08/12/2024 | -15.95% | Wells Fargo | $60 → $61 | Maintains | Equal-Weight | |||
08/09/2024 | -13.2% | Deutsche Bank | $64 → $63 | Maintains | Hold | |||
08/08/2024 | -13.2% | Barclays | $65 → $63 | Maintains | Equal-Weight | |||
08/08/2024 | -14.58% | Cantor Fitzgerald | $58 → $62 | Maintains | Neutral | |||
08/08/2024 | -14.58% | Evercore ISI Group | $65 → $62 | Maintains | Outperform | |||
07/23/2024 | -20.09% | Cantor Fitzgerald | $58 → $58 | Reiterates | Neutral → Neutral | |||
06/12/2024 | -20.09% | Cantor Fitzgerald | $58 → $58 | Reiterates | Neutral → Neutral | |||
05/30/2024 | 18.49% | JP Morgan | $101 → $86 | Maintains | Overweight | |||
05/30/2024 | -15.95% | Baird | → $61 | Initiates | → Neutral | |||
05/08/2024 | 10.22% | Argus Research | $100 → $80 | Maintains | Buy | |||
05/07/2024 | -17.33% | Wells Fargo | $76 → $60 | Maintains | Equal-Weight | |||
05/07/2024 | -18.71% | TD Cowen | $99 → $59 | Downgrade | Buy → Hold | |||
05/02/2024 | 6.09% | B of A Securities | $95 → $77 | Maintains | Buy | |||
05/02/2024 | 1.96% | Goldman Sachs | $85 → $74 | Maintains | Buy | |||
05/02/2024 | -13.2% | Barclays | $78 → $63 | Maintains | Equal-Weight | |||
05/02/2024 | -17.33% | UBS | $85 → $60 | Downgrade | Buy → Neutral | |||
05/02/2024 | -9.07% | Truist Securities | $90 → $66 | Reiterates | Buy → Buy | |||
05/02/2024 | -0.8% | Mizuho | $86 → $72 | Maintains | Buy | |||
05/01/2024 | -17.33% | Leerink Partners | → $60 | Downgrade | Outperform → Market Perform | |||
05/01/2024 | -20.09% | Cantor Fitzgerald | $87 → $58 | Downgrade | Overweight → Neutral | |||
04/10/2024 | 19.87% | Cantor Fitzgerald | $87 → $87 | Reiterates | Overweight → Overweight | |||
04/08/2024 | 4.71% | Wells Fargo | $83 → $76 | Maintains | Equal-Weight | |||
04/04/2024 | 19.87% | Cantor Fitzgerald | $87 → $87 | Reiterates | Overweight → Overweight | |||
03/15/2024 | 29.51% | Piper Sandler | $93 → $94 | Maintains | Overweight | |||
03/06/2024 | 7.47% | Barclays | → $78 | Initiates | → Equal-Weight | |||
02/26/2024 | 21.25% | Leerink Partners | → $88 | Initiates | → Outperform | |||
02/08/2024 | 19.87% | Cantor Fitzgerald | $87 → $87 | Reiterates | Overweight → Overweight | |||
02/08/2024 | 15.73% | RBC Capital | $86 → $84 | Maintains | Outperform | |||
12/22/2023 | 29.51% | HSBC | → $94 | Initiates | → Buy | |||
12/11/2023 | 36.4% | TD Cowen | $102 → $99 | Maintains | Outperform | |||
11/21/2023 | 19.87% | Cantor Fitzgerald | → $87 | Reiterates | Overweight → Overweight | |||
11/02/2023 | 18.49% | Mizuho | $88 → $86 | Maintains | Buy | |||
11/02/2023 | 18.49% | RBC Capital | $91 → $86 | Maintains | Outperform | |||
11/02/2023 | 37.78% | Morgan Stanley | $110 → $100 | Maintains | Overweight | |||
09/19/2023 | 14.36% | Evercore ISI Group | $81 → $83 | Upgrade | In-Line → Outperform | |||
09/14/2023 | 19.87% | Cantor Fitzgerald | → $87 | Reiterates | Overweight → Overweight | |||
09/12/2023 | 10.22% | Wolfe Research | → $80 | Upgrade | Peer Perform → Outperform | |||
09/01/2023 | 12.98% | Piper Sandler | $85 → $82 | Maintains | Overweight | |||
08/18/2023 | 25.38% | RBC Capital | → $91 | Reiterates | Outperform → Outperform | |||
08/18/2023 | — | Edward Jones | — | Downgrade | Buy → Hold | |||
08/04/2023 | 17.11% | Raymond James | $90 → $85 | Maintains | Outperform | |||
08/03/2023 | 35.02% | Truist Securities | $103 → $98 | Maintains | Buy | |||
08/03/2023 | 51.56% | Morgan Stanley | $120 → $110 | Maintains | Overweight | |||
08/03/2023 | 25.38% | RBC Capital | $102 → $91 | Maintains | Outperform | |||
08/03/2023 | 18.49% | Barclays | $89 → $86 | Maintains | Overweight | |||
07/12/2023 | 22.62% | Barclays | $90 → $89 | Maintains | Overweight | |||
07/11/2023 | 21.25% | Mizuho | $120 → $88 | Maintains | Buy | |||
07/07/2023 | 46.05% | JP Morgan | $114 → $106 | Maintains | Overweight | |||
06/20/2023 | 41.91% | Truist Securities | $109 → $103 | Maintains | Buy | |||
05/30/2023 | 57.07% | JP Morgan | $125 → $114 | Maintains | Overweight | |||
05/26/2023 | 17.11% | Piper Sandler | → $85 | Initiates | → Overweight | |||
05/09/2023 | 40.53% | RBC Capital | → $102 | Reiterates | → Outperform | |||
05/08/2023 | 4.71% | Wells Fargo | $95 → $76 | Maintains | Equal-Weight | |||
05/08/2023 | 32.27% | Credit Suisse | $125 → $96 | Maintains | Outperform | |||
05/08/2023 | 24% | Raymond James | $110 → $90 | Maintains | Outperform | |||
05/05/2023 | 21.25% | Goldman Sachs | $100 → $88 | Maintains | Buy |
FAQ
Quel est le cours indicatif de l'action CVS Health (CVS) ?
Le dernier objectif de prix pour CVS Health (NYSE:CVS) a été rapporté par Cantor Fitzgerald le août 26, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $78.00 s'attendant à ce que CVS se rise dans les 12 prochains mois (un possible changement de 7.47% upside). 43 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour CVS Health (CVS) ?
La dernière note d'analyste pour CVS Health (NYSE:CVS) a été fournie par Cantor Fitzgerald, et CVS Health réitéré leur note overweight.
Quand a eu lieu la dernière mise à niveau pour CVS Health (CVS) ?
La dernière amélioration pour CVS Health Corp a eu lieu le août 18, 2025 lorsque UBS a augmenté leur objectif de prix à $79. UBS avait précédemment a neutral pour CVS Health Corp.
Quand a eu lieu la dernière dégradation pour CVS Health (CVS) ?
La dernière réduction pour CVS Health Corp a eu lieu le mai 7, 2024 lorsque TD Cowen a changé leur objectif de prix de $99 à $59 pour CVS Health Corp.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour CVS Health (CVS) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de CVS Health, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour CVS Health a été déposée le août 26, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers août 26, 2026.
La note d'analyste pour CVS Health (CVS) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de CVS Health (CVS) était un réitéré avec un objectif de prix de $78.00 à $78.00. Le prix actuel de CVS Health (CVS) est de $72.58, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.